Your browser doesn't support javascript.
loading
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis.
Alborzinia, Hamed; Flórez, Andrés F; Kreth, Sina; Brückner, Lena M; Yildiz, Umut; Gartlgruber, Moritz; Odoni, Dorett I; Poschet, Gernot; Garbowicz, Karolina; Shao, Chunxuan; Klein, Corinna; Meier, Jasmin; Zeisberger, Petra; Nadler-Holly, Michal; Ziehm, Matthias; Paul, Franziska; Burhenne, Jürgen; Bell, Emma; Shaikhkarami, Marjan; Würth, Roberto; Stainczyk, Sabine A; Wecht, Elisa M; Kreth, Jochen; Büttner, Michael; Ishaque, Naveed; Schlesner, Matthias; Nicke, Barbara; Stresemann, Carlo; Llamazares-Prada, María; Reiling, Jan H; Fischer, Matthias; Amit, Ido; Selbach, Matthias; Herrmann, Carl; Wölfl, Stefan; Henrich, Kai-Oliver; Höfer, Thomas; Trumpp, Andreas; Westermann, Frank.
Afiliação
  • Alborzinia H; Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany. hamed.alborzy@gmail.com.
  • Flórez AF; Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany. hamed.alborzy@gmail.com.
  • Kreth S; Division of Stem Cells and Cancer German Cancer Research Center and Center for Molecular Biology of the University of Heidelberg Alliance, Heidelberg, Germany. hamed.alborzy@gmail.com.
  • Brückner LM; Division of Theoretical Systems Biology, German Cancer Research Center, Heidelberg, Germany.
  • Yildiz U; Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.
  • Gartlgruber M; Hopp Children's Cancer Center, Heidelberg, Germany.
  • Odoni DI; Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.
  • Poschet G; Hopp Children's Cancer Center, Heidelberg, Germany.
  • Garbowicz K; Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.
  • Shao C; Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.
  • Klein C; Division of Stem Cells and Cancer German Cancer Research Center and Center for Molecular Biology of the University of Heidelberg Alliance, Heidelberg, Germany.
  • Meier J; Hopp Children's Cancer Center, Heidelberg, Germany.
  • Zeisberger P; Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.
  • Nadler-Holly M; Bioinformatics and Omics Data Analytics, German Cancer Research Center, Heidelberg, Germany.
  • Ziehm M; Biomedical Informatics, Data Mining and Data Analytics, Augsburg University, Augsburg, Germany.
  • Paul F; Metabolomics Core Technology Platform, University of Heidelberg, Heidelberg, Germany.
  • Burhenne J; Hopp Children's Cancer Center, Heidelberg, Germany.
  • Bell E; Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.
  • Shaikhkarami M; Division of Theoretical Systems Biology, German Cancer Research Center, Heidelberg, Germany.
  • Würth R; Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.
  • Stainczyk SA; Division of Stem Cells and Cancer German Cancer Research Center and Center for Molecular Biology of the University of Heidelberg Alliance, Heidelberg, Germany.
  • Wecht EM; Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.
  • Kreth J; Division of Stem Cells and Cancer German Cancer Research Center and Center for Molecular Biology of the University of Heidelberg Alliance, Heidelberg, Germany.
  • Büttner M; Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.
  • Ishaque N; Division of Stem Cells and Cancer German Cancer Research Center and Center for Molecular Biology of the University of Heidelberg Alliance, Heidelberg, Germany.
  • Schlesner M; Proteome Dynamics, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
  • Nicke B; Proteome Dynamics, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
  • Stresemann C; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
  • Llamazares-Prada M; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Reiling JH; Hopp Children's Cancer Center, Heidelberg, Germany.
  • Fischer M; Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.
  • Amit I; Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany.
  • Selbach M; Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.
  • Herrmann C; Division of Stem Cells and Cancer German Cancer Research Center and Center for Molecular Biology of the University of Heidelberg Alliance, Heidelberg, Germany.
  • Wölfl S; Hopp Children's Cancer Center, Heidelberg, Germany.
  • Henrich KO; Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.
  • Höfer T; Hopp Children's Cancer Center, Heidelberg, Germany.
  • Trumpp A; Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.
  • Westermann F; Hopp Children's Cancer Center, Heidelberg, Germany.
Nat Cancer ; 3(4): 471-485, 2022 04.
Article em En | MEDLINE | ID: mdl-35484422
ABSTRACT
Aberrant expression of MYC transcription factor family members predicts poor clinical outcome in many human cancers. Oncogenic MYC profoundly alters metabolism and mediates an antioxidant response to maintain redox balance. Here we show that MYCN induces massive lipid peroxidation on depletion of cysteine, the rate-limiting amino acid for glutathione (GSH) biosynthesis, and sensitizes cells to ferroptosis, an oxidative, non-apoptotic and iron-dependent type of cell death. The high cysteine demand of MYCN-amplified childhood neuroblastoma is met by uptake and transsulfuration. When uptake is limited, cysteine usage for protein synthesis is maintained at the expense of GSH triggering ferroptosis and potentially contributing to spontaneous tumor regression in low-risk neuroblastomas. Pharmacological inhibition of both cystine uptake and transsulfuration combined with GPX4 inactivation resulted in tumor remission in an orthotopic MYCN-amplified neuroblastoma model. These findings provide a proof of concept of combining multiple ferroptosis targets as a promising therapeutic strategy for aggressive MYCN-amplified tumors.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ferroptose / Neuroblastoma Tipo de estudo: Prognostic_studies Limite: Child / Humans Idioma: En Revista: Nat Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ferroptose / Neuroblastoma Tipo de estudo: Prognostic_studies Limite: Child / Humans Idioma: En Revista: Nat Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha